Disclaimer for the US market

The products and information provided on this website are intended for healthcare professionals. These products are not for sale or distribution in the United States and statements made regarding these products have not been evaluated by the U.S. Food and Drug Administration (FDA). The efficacy of these products has not been confirmed by FDA-approved research and these products are therefore not intended to diagnose, treat, cure or prevent any disease. All information presented here is for general information purposes only and not meant as a substitute for or alternative to advice from healthcare practitioners. The Federal Food, Drug and Cosmetic Act requires this notice.

Neither the Company nor its representatives is providing any medical advice, and none should be inferred, from any ideas, suggestions, testimonials or other information set forth on this website or in other Company materials or provided over the phone, in the mail, in product packaging, or in email correspondence. This website may contain links to third-party websites. The Company provides these links as a convenience only and does not endorse any of these sites. The Company is not responsible for the content of, and does not make any representations regarding the materials on, such linked third-party websites. If you decide to access or rely on information at linked third-party website, you do so at our own risk. Our terms and conditions, including disclaimers, are more fully set forth in our Terms of Use, Privacy Policy and Terms of Online Sales.

Strategic sales partnership between Resuscitec and WEINMANN Emergency  

With immediate effect WEINMANN Emergency distributes the CARL Technology of Resuscitec in France via its subsidiary WEINMANN Emergency France. CARL is an advanced concept for extracorporeal resuscitation of patients after cardiovascular arrest, which can be used both in-hospital and prehospital.    

WEINMANN Emergency is an internationally active medical technology company that has been setting new standards in saving lives for years with its transportable solutions for emergency, transport and disaster medicine.  

Resuscitec develops, produces and markets advanced emergency solutions with its CARL product division, with a strong specialization in the field of extracorporeal cardiopulmonary resuscitation of patients after acute cardiovascular arrest.  

With the joint brand entry, both companies aim to further strengthen the French chain of survial and provide patients sudden after cardiac arrest with a better prognosis for neurologically intact survival.  

The first joint appearance will take place during “Urgences 2023”, in Paris, from June 07 to 09. More information can be found on www.weinmann-emergency.com


< Back